Omeros Corporation OMER

Company Overview

Omeros Corporation is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic, inflammatory, and central nervous system disorders. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with research programs centered on complement-mediated diseases, addiction, and neurodegenerative conditions. Historically, Omeros generated commercial revenue from OMIDRIA, an ophthalmic product used during cataract surgery, although rights to the product were later divested while the company retained certain economic interests tied to royalties and milestones.

The company’s primary value drivers are its proprietary therapeutic pipeline and intellectual property portfolio, particularly programs involving the lectin pathway of the complement system and phosphodiesterase inhibition technologies. Omeros has positioned itself around targeted therapies for rare and difficult-to-treat diseases, emphasizing biologic and small-molecule approaches with potential orphan-drug applications. Founded in 1994 and headquartered in Seattle, Washington, the company evolved from an early-stage platform biotechnology company into a clinically focused biopharmaceutical developer with multiple investigational assets and prior commercial-stage operations.